Xeris Biopharma Holdings, Inc. Common Stock (XERS) is a publicly traded Healthcare sector company. As of October 24, 2026, XERS trades at $10.24 with a market cap of $1.98B and a P/E ratio of -102.15. XERS moved -6.17% today. Year to date, XERS is +43.86%; over the trailing twelve months it is +11.72%. Its 52-week range spans $3.59 to $11.42. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces XERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
XERS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. XERS recently traded at $10.24. Market cap is $1.98B. P/E ratio is -102.15. Revenue is $335.41M.
| Metric | Value |
|---|---|
| Price | $10.24 |
| Market Cap | $1.98B |
| P/E Ratio | -102.15 |
| EPS | $-0.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.42 |
| 52-Week Low | $3.59 |
| Volume | 2.09M |
| Avg Volume | 0 |
| Revenue (TTM) | $335.41M |
| Net Income | $-17.16M |
| Gross Margin | 0.00% |
6 analysts cover XERS: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.